# US 6,730,477 B1 · Method of diagnosing, monitoring and staging breast cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,477 B1
- Document ID: US6730477B1
- Status: Granted
- Kind: B1
- Application number: 09/664,249
- Filed: 2000-09-18
- Granted: 2004-05-04
- Earliest claimed: 1998-08-04
- Assignees: diaDexus, Inc.
- Inventors: Yongming Sun; Susana Salceda; Herve Recipon
- Web page: https://patentgrep.com/patent/US6730477B1

## CPC

- A61K 51/1051: {the tumor cell being from breast, e.g. the antibody being herceptin}
- A61K 49/16: Antibodies; Immunoglobulins; Fragments thereof
- C07K 16/3015: {Breast}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57515: of the breast
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 2039/505: {comprising antibodies}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/136: Screening for pharmacological compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a new method for detecting, diagnosing, monitoring, staging, and prognosticating breast cancer.

## Claims

### Claim 1

A method for diagnosing the presence of breast cancer in a patient comprising:
(a) measuring levels of a breast specific gene (BSG) in cells, tissues or bodily fluids in said patient; and
(b) comparing measured levels of BSG with levels of BSG in cells, tissues or bodily fluids from a normal human control,
wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
wherein a change in measured levels of BSG in the patient versus normal human control is associated with the presence of breast cancer.

### Claim 2

A method of diagnosing metastatic breast cancer in a patient having breast cancer comprising:
(a) identifying a patient having breast cancer that is not known to have metastasized;
(b) measuring levels of a breast specific gene (BSG) in a sample of cells, tissues, or bodily fluid from said patient; and
(c) comparing the measured BSG levels with levels of BSG in cells, tissue, or bodily fluid type of a normal human control,
wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
wherein a change in measured BSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

### Claim 3

A method of staging breast cancer in a patient comprising:
(a) identifying a patient having breast cancer;
(b) measuring levels of a breast specific gene (BSG) in a sample of cells, tissues, or bodily fluid from said patient for BSG; and
(c) comparing measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control sample,
wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
wherein a change in measured BSG levels in said patient versus the normal human control is associated with a cancer which is progressing or regressing or in remission.

### Claim 4

A method of monitoring breast cancer in a patient, having breast cancer for the onset of metastasis comprising:
(a) identifying a patient having breast cancer that is not known to have metastasized;
(b) periodically measuring breast specific gene (BSG) levels in a sample of cells, tissues, or bodily fluid from said patient; and
(c) comparing the measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control, wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 and wherein a change in BSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

### Claim 5

A method of monitoring the change in stage of breast cancer in a patient having breast cancer comprising:
(a) identifying a patient having breast cancer;
(b) periodically measuring breast specific gene (BSG) levels in a sample of cells, tissues, or bodily fluid from said patient; and
(c) comparing the measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control,
wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
wherein a change in measured BSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage, which is regressing in stage, or in remission.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of claim 1, 2, 3, 4 or 5 wherein the change associated with the presence, metastasis or progression of breast cancer in said patient is an increase in measured BSG levels in the patient and the BSG comprises Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4 or SEQ ID NO:10) or Mam005 (SEQ ID NO:3).

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of claim 1, 2, 3, 4 or 5 wherein the change associated with the presence, metastasis or progression of breast cancer in said patient is a decrease in measured BSG levels in the patient and the BSG comprises Mam002 (SEQ ID NO:1).

### Claim 8 (depends on 3, 5)

The method of claim 3 or 5 wherein the change associated with the regression or remission of breast cancer in said patient is a decrease in measured BSG levels in the patient and the BSG comprises Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4 or SEQ ID NO:10) or Mam005 (SEQ ID NO:3).

### Claim 9 (depends on 3, 5)

The method of claim 3 or 5 wherein the change associated with the regression or remission of breast cancer in said patient is an increase in measured BSG levels in the patient and the BSG comprises Mam002 (SEQ ID NO:1).

### Claim 10 (depends on 1, 2, 3, 4)

The method of claim 1, 2, 3, 4, or 5 wherein the BSG comprises Mam004 (SEQ ID NO:4).

### Claim 11 (depends on 1)

The method of claim 1 wherein the BSG comprises Mam004 (SEQ ID NO:4).

### Claim 12 (depends on 1, 2, 3, 4)

The method of claim 1, 2, 3, 4, or 5 wherein the BSG comprises Mam005 (SEQ ID NO:5).

### Claim 13 (depends on 1)

The method of claim 1 wherein the BSG comprises Mam005 (SEQ ID NO:5).
